



ERRATUM

**Erratum found in «Farmacia Hospitalaria.  
2021;45(3):126-34»**

Eduardo Tejedor-Tejada<sup>1</sup>, Pablo Nieto-Guindo<sup>1</sup>, Javier Tejedor-Tejada<sup>2</sup>,  
Estrella Martínez-Velasco<sup>1</sup>, Araceli Gómez-Sánchez<sup>3</sup>

<sup>1</sup>Department of Hospital Pharmacy, Hospital Universitario Torrecárdenas, Almería. Spain. <sup>2</sup>Department of Digestive Surgery, Hospital Universitario Río Hortega, Valladolid. Spain. <sup>3</sup>Department of Hospital Pharmacy, Hospital Costa del Sol, Marbella. Spain.

: Received 25 April 2022;  
: Accepted 30 April 2022.  
: Early Access date (05/05/2022).  
: DOI: 10.7399/fh.13281

An error has been detected in the English version of the article **«A guide for the administration of oral antineoplastic in patients with swallowing disorders»**, published in **Farm Hosp. 2021;46(3):126-34**:

In Table 1. Line 1 relative to ABIRATERONE film-coated tablets (Zytiga®).

Where it says:

The manufacturer recommends crushing or dissolving the product due to a potential decrease in efficacy.

Have to say:

The manufacturer no recommends crushing or dissolving the product due to a potential decrease in efficacy.

